SCHEMBL13250415

SCHEMBL13250415

Cc1nc2c(c(=O)n1C(c1ccccc1)c1ccccc1)CCN(C(=O)Oc1ccc(OC(F)F)cc1)C2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 2/20 0.40
TRPV1 Q8NER1 7/20 0.39
FAAH O00519 3/20 0.39
USP2 O75604 4/20 0.37
CYP3A4 P08684 3/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C9 P11712 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP2D6 P10635 2/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
MAPT P10636 1/20 0.34
RECQL P46063 1/20 0.34
USP7 Q93009 1/20 0.33
PDE10A Q9Y233 1/20 0.33
LIPE Q05469 1/20 0.33
MTOR P42345 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13249795 0.92 MGLL (0.47) MGLLTRPV1FAAHUSP2CYP3A4
SCHEMBL13249801 0.91 MGLL (0.41) MGLLTRPV1FAAHUSP2CYP3A4
SCHEMBL13249797 0.91 MGLL (0.42) MGLLTRPV1FAAHUSP2CYP3A4
SCHEMBL13249800 0.90 MGLL (0.42) MGLLTRPV1FAAHUSP2CYP3A4
SCHEMBL13250298 0.89 MGLL (0.43) MGLLTRPV1FAAHUSP2CYP3A4
SCHEMBL13249814 0.89 MGLL (0.41) MGLLTRPV1FAAHUSP2CYP3A4
SCHEMBL13249804 0.89 MGLL (0.41) MGLLTRPV1FAAHUSP2CYP3A4
SCHEMBL13249945 0.89 LIPE (0.43) MGLLTRPV1FAAHLIPE
SCHEMBL13250081 0.89 MGLL (0.39) MGLLTRPV1FAAHUSP2CYP3A4
SCHEMBL13249941 0.87 MGLL (0.43) MGLLTRPV1FAAHUSP2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION 2010-07-29 US disclosed
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GCGR, GPR65 MGLL 882/4885TRPV1 632/4885FAAH 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.